Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter A Calabresi

Showing results (1-10 of 464) with videos related to

Pageof 47
Sort By:
Neurology|April 24, 2002
Considerations in the treatment of relapsing-remitting multiple sclerosisPeter A Calabresi
The New England Journal of Medicine|December 14, 2011
Inflammation in multiple sclerosis--sorting out the gray matterPeter A Calabresi
The New England Journal of Medicine|December 22, 2016
B-Cell Depletion - A Frontier in Monoclonal Antibodies for Multiple SclerosisPeter A Calabresi
The Lancet. Neurology|August 21, 2021
Trials and tribulations on the path to remyelinationPeter A Calabresi
The New England Journal of Medicine|May 14, 2025
Progress toward Mitigating Disability Progression in Multiple SclerosisPeter A Calabresi
Nature Clinical Practice. Neurology|September 5, 2007
Investigating glatiramer acetate for relapsing-remitting multiple sclerosis at the double dose--is more better?Peter A Calabresi
The Lancet. Neurology|December 22, 2017
Advances in multiple sclerosis: from reduced relapses to remediesPeter A Calabresi
American Family Physician|December 2, 2004
Diagnosis and management of multiple sclerosisPeter A Calabresi
Neurology|February 16, 2021
Is Cerebrospinal Fluid Responsible for Innate Immune Cell Activation and Neurotoxicity in Multiple Sclerosis?Grigorios Kalaitzidis, Peter A Calabresi
Neurology|February 4, 2009
Natalizumab: bound to rebound?Nicoline Schiess, Peter A Calabresi
Pageof 47

Showing results (1-10 of 464) with videos related to

Sort By:
Pageof 47
Neurology|April 24, 2002
Considerations in the treatment of relapsing-remitting multiple sclerosisPeter A Calabresi
The New England Journal of Medicine|December 14, 2011
Inflammation in multiple sclerosis--sorting out the gray matterPeter A Calabresi
The New England Journal of Medicine|December 22, 2016
B-Cell Depletion - A Frontier in Monoclonal Antibodies for Multiple SclerosisPeter A Calabresi
The Lancet. Neurology|August 21, 2021
Trials and tribulations on the path to remyelinationPeter A Calabresi
The New England Journal of Medicine|May 14, 2025
Progress toward Mitigating Disability Progression in Multiple SclerosisPeter A Calabresi
Nature Clinical Practice. Neurology|September 5, 2007
Investigating glatiramer acetate for relapsing-remitting multiple sclerosis at the double dose--is more better?Peter A Calabresi
The Lancet. Neurology|December 22, 2017
Advances in multiple sclerosis: from reduced relapses to remediesPeter A Calabresi
American Family Physician|December 2, 2004
Diagnosis and management of multiple sclerosisPeter A Calabresi
Neurology|February 16, 2021
Is Cerebrospinal Fluid Responsible for Innate Immune Cell Activation and Neurotoxicity in Multiple Sclerosis?Grigorios Kalaitzidis, Peter A Calabresi
Neurology|February 4, 2009
Natalizumab: bound to rebound?Nicoline Schiess, Peter A Calabresi
Pageof 47